Evidence map›Paper›PMID 39020082›Full record

ArticleCommunications biology2024

Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system

Philipp A Ilinykh, Kai Huang, Bronwyn M Gunn, Natalia A Kuzmina, Kritika Kedarinath, Eduardo Jurado-Cobena, Fuchun Zhou, Chandru Subramani, Matthew A Hyde, Jalene V Velazquez and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Philipp A IlinykhDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Kai HuangDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-3373-5594
Bronwyn M GunnRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8904-9334
Natalia A KuzminaDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-6650-9369
Kritika KedarinathDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Eduardo Jurado-CobenaDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-8832-4645
Fuchun ZhouDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Chandru SubramaniDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Matthew A HydeGalveston National Laboratory, Galveston, TX, USA.
Jalene V VelazquezPaul G. Allen School of Global Health, Washington State University, Pullman, WA, USA.
Lauren E WilliamsonVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-2725-5826
Pavlo GilchukVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Robert H CarnahanVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-5230-1532
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Galit.Alter@modernatx.com.
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. james.crowe@vumc.org.ORCID 0000-0002-0049-1079
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA. alexander.bukreyev@utmb.edu.ORCID 0000-0002-0342-4824

Funding

Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for FilovirusesU19AI142785 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2019 to 2023
$35.5M
NIAID NIH HHS U19 AI142785
6 · The paper itself

Abstract

Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated effects are known to contribute the protection conferred by antibodies of various epitope specificities. At the same time, the role of the complement system remains unclear. Here, we compare complement activation by two groups of representative monoclonal antibodies (mAbs) interacting with the glycan cap (GC) or the membrane-proximal external region (MPER) of GP. Binding of GC-specific mAbs to GP induces complement-dependent cytotoxicity (CDC) in the GP-expressing cell line via C3 deposition on GP in contrast to MPER-specific mAbs. In the mouse model of EBOV infection, depletion of the complement system leads to an impairment of protection exerted by one of the GC-specific, but not MPER-specific mAbs. Our data suggest that activation of the complement system represents an important mechanism of antiviral protection by GC antibodies.

Indexed as

Antibodies, MonoclonalAntibodies, ViralEbolavirusHemorrhagic Fever, EbolaPolysaccharidesViral Envelope ProteinsAnimalsComplement ActivationComplement System ProteinsFemaleGlycoproteinsHumansMiceMice, Inbred BALB CAntibodies, MonoclonalAntibodies, ViralComplement System Proteinsenvelope glycoprotein, Ebola virusGlycoproteinsPolysaccharidesViral Envelope Proteins

Identifiers

PMID39020082
PMCPMC11255267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.